by | Mar 13, 2025 | Lupus Foundation of America
March is Kidney Month! In November 2024, the American College of Rheumatology (ACR) released a summary of their new guidelines for the screening, treatment, and management of lupus nephritis.What is important for a patient with lupus nephritis to know? We have answers...
by | Mar 13, 2025 | Lupus Foundation of America
March is Kidney Month! In November 2024, the American College of Rheumatology (ACR) released a summary of their new guidelines for the screening, treatment, and management of lupus nephritis.What is important for a patient with lupus nephritis to know? We have answers...
by | Mar 11, 2025 | Lupus Foundation of America, News & Events
A new study looked at the effectiveness of the modified National Institute of Health (mNIH) activity and chronicity scoring system for predicting end-stage kidney disease (ESKD) among Latin American individuals with lupus nephritis (LN). This retrospective study...
by | Mar 6, 2025 | Lupus Foundation of America, News & Events
A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus (SLE) with persistently active disease (PAD). Researchers found that both flares and PAD significantly contribute to damage accrual in people with...
by | Mar 5, 2025 | Lupus Foundation of America, News & Events
Today, the U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for Gazyva® (Obinutuzumab), for the potential treatment of lupus nephritis, (LN, lupus-related kidney disease). A sBLA is a request submitted...
by | Feb 28, 2025 | Lupus Foundation of America, News & Events
Abnormal expression and function of microRNA-203 have been linked to various autoimmune diseases, including rheumatoid arthritis and psoriasis. In a new study, researchers investigated microRNA-203 as a potential biomarker for lupus nephritis (LN) and found that...
